Sector News

EU clears plans by drugmakers GSK and Novartis to trade assets

January 29, 2015
Life sciences
(Reuters) – The European Commission on Wednesday approved a plan by Novartis (NOVN.VX) and GlaxoSmithKline (GSK.L) to trade more than $20 billion worth of assets, part of a reshaping of the drug industry at a time of healthcare spending cuts and more competition.
 
The companies agreed last April to the transaction that includes GSK buying Novartis’ vaccines business, Novartis purchasing GSK’s cancer drugs, and the two groups tying up in consumer healthcare.
 
The Swiss drugmaker will buy London-based GSK’s oncology products for $14.5 billion plus another $1.5 billion that depends on the results of a trial in melanoma.
 
The Commission said its approval was conditional on the divestment of two of Novartis’s cancer treatments – LGX818, a B-Raf inhibitor, and MEK162, an MEK inhibitor.
 
B-Raf inhibitors and MEK inhibitors are therapies that block cell proliferation, responsible for tumour growth and progression, and can be used to treat a number of different cancers.
 
The Commission said it had concerns that the transaction would have reduced competition and innovation for these products, but that the commitments address these concerns.
 
GSK is buying Novartis’ vaccines, excluding influenza, for $5.25 billion plus potential milestone payments of up to $1.8 billion and ongoing royalties. The companies also will form a joint venture in consumer healthcare.
 
“The decision is conditional upon the divestiture of assets in the vaccines and consumer health businesses,” the Commission, which acts as the EU’s anti-trust watchdog, said in a statement.
 
GSK has committed to divest one meningitis vaccine, grant a worldwide licence of another and offer further concessions in Germany and Italy, the Commission said.
 
The Commission had concerns the deal would hurt competition on developing meningitis and diphtheria tetanus vaccines, as well as products to stop smoking and to treat colds and pain.
 
GSK said that in Europe and Turkey, it had agreed to sell its NiQuitin products that help stop smoking and its Coldrex cold and flu products. In Sweden, it would sell its Panodil pain management, as well as its Nezeril/Nasin cold and flu products.
 
Novartis will sell its cold sore business in Europe.
 
GSK said it planned to complete the transactions with Novartis during the first six months of this year.
 
(Reporting by Philip Blenkinsop and Robin Emmott, editing by David Evans)

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]